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OBJECTIVES This study was designed to assess the association between 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibition, coronary endothelial function and cytokine
activation in heart transplant recipients without angiographically detectable disease.
BACKGROUND Coronary endothelial dysfunction contributes to cardiac allograft vasculopathy. The vasopro-
tective effects of statins in heart transplant recipients may include restoration of endothelial
function and suppression of allograft inflammatory activity.
METHODS Heart transplant recipients (one to three years after heart transplant) were divided into three
groups based on the total cholesterol levels: group 1 (n 5 21), patients with a history of
hypercholesterolemia adequately controlled with simvastatin; group 2 (n 5 19), patients with
hypercholesterolemia not adequately treated with simvastatin; and group 3 (n 5 40), patients
without hypercholesterolemia. Coronary vasomotor function and intimal thickness as well as
coronary sinus and aortic cytokine concentrations (tumor necrosis factor [TNF]-a, interleu-
kin [IL]-6 and soluble IL-2 receptor) were investigated. In a prospective one-year follow-up
study, changes in coronary endothelial function and cytokine levels were compared between
11 hypercholesterolemic patients treated with simvastatin and 9 controls.
RESULTS Epicardial and microvascular endothelial functions were better in groups 1 and 3 than they
were in group 2 (p , 0.01 and p , 0.05). Transcardiac IL-6 and TNF-a gradients were
significantly increased in groups 2 and 3 compared with group 1 (IL-6: p , 0.05; TNF-a:
p , 0.01). Plaque areas were significantly increased in groups 1 and 2 (p , 0.05 vs. group 3),
whereas lumen area was increased in group 2 compared with group 1 (p , 0.05), demonstrating
adaptive vascular remodeling. In patients treated with simvastatin, coronary endothelial function
and cardiac cytokine activity significantly improved during the one-year follow-up.
CONCLUSIONS Inhibition of allograft inflammatory activity and attenuation of the coronary endothelial
dysfunction observed in cardiac transplant recipients during treatment with simvastatin
may represent an important mechanism by which HMG-CoA reductase inhibitors protect
against the development of cardiac allograft vasculopathy. (J Am Coll Cardiol 2001;38:
814–8) © 2001 by the American College of Cardiology
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors have been shown to reduce cardiac
allograft vasculopathy in human heart transplant recipients
(1,2). These effects result from as yet unknown mechanisms
not clearly attributable to lipid lowering. 3-Hydroxy-3-
methylglutaryl coenzyme A reductase inhibition has been
shown in vitro and in vivo to restore endothelial dysfunction
in the nontransplanting setting (3–5). Immunologic reac-
tions including interactions between cytokines and endo-
thelial cells appear to play a crucial role in the chronic
immune activation related to the development of transplant
atherosclerosis (6). Therefore, this study was designed to
assess the association between hypercholesterolemia and
cholesterol-lowering therapy with the HMG-CoA reduc-
tase inhibitor simvastatin on coronary endothelial dysfunc-
tion, coronary morphology and cytokine concentrations in
human heart transplant recipients.
PATIENTS AND METHODS
Patient population. This investigation was performed
with approval by the Institutional Ethics Committee. In-
formed consent was obtained from all subjects. The study
group consisted of 80 consecutive patients undergoing
routine diagnostic coronary angiography one to three years
after orthotopic heart transplantation. Patients were selected
from a group of 108 consecutively studied transplant recip-
ients (one to three years after transplantation) according to
predefined exclusion criteria: acute rejection (International
Society of Heart and Lung Transplantation grade $1b;
n 5 2) or infection episode (C-reactive protein [CRP]
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$1 mg/dl; n 5 4) at the time of the study, serum creatinine
.1.8 mg/dl (n 5 9), glutamic-pyruvic-transaminase
.120 mg/dl (n 5 4) or fasting glucose concentration
.140 mg/dl (n 5 3). Moreover, patients with angiographi-
cally visible coronary artery disease were excluded (n 5 6).
The remaining 80 patients were in the fasting state, and all
cardiovascular medications (angiotensin-converting enzyme
inhibitors, calcium-antagonists, beta-blockers and aspirin)
had been discontinued for at least 24 h. All patients studied
were maintained on a tacrolimus and mycophenolate
mofetil-based immunosuppression protocol. The 80 pa-
tients of this study were divided into three groups according
to their history of hypercholesterolemia and their total
serum cholesterol level at the time of the study. Escobar et
al. (7) have demonstrated that total cholesterol level is an
independent predictor of severity of cardiac allograft vascu-
lopathy as detected by intravascular ultrasound (IVUS). A
total cholesterol level of .240 mg/dl was used for the
definition of hypercholesterolemia (5,8). Venous blood
specimens were obtained after a 12-h fast. Group 1 con-
sisted of 21 patients who had been previously ($6 months)
diagnosed with hypercholesterolemia and had reduced their
total cholesterol levels to ,240 mg/dl using 10 mg simva-
statin. Group 2 consisted of 19 patients who had been
previously ($6 months) diagnosed with hypercholesterol-
emia and had failed to reduce their total cholesterol levels to
,240 mg/dl despite 10 mg simvastatin treatment. Group 3
consisted of 40 patients without hypercholesterolemia and
without simvastatin treatment. The number of patients at
one, two and three years after transplant in each of the three
study groups were not significantly different. Detailed pa-
tient characteristics are listed in Table 1. The prospective
study groups consisted of 11 simvastatin-treated patients
and 9 normocholesterolemic controls. Patients were studied
before starting simvastatin (baseline) and after a follow-up
period of 12 months.
Methods. First, a routine biopsy was taken via a trans-
venous approach to exclude acute rejection. A 6F multipur-
pose catheter was then placed in the coronary sinus, and a
blood sample (10 ml) was withdrawn for determination of
cytokine concentrations (interleukin [IL]-6, soluble inter-
leukin [sIL]2R, tumor necrosis factor [TNF]-a). Blood
samples (10 ml) were withdrawn from the aortic root for
determination of circulating cytokines. Measurements of
coronary vasomotor response (quantitative coronary angiog-
raphy and intracoronary Doppler flow measurement) and
determination of intimal thickening (IVUS) have been
described in detail elsewhere (9,10). In brief, following the
diagnostic procedure including left ventriculography and
coronary angiography, a Doppler Flow-wire (FloWire, Car-
diometrics Inc., Mountain View, California) was placed in
the proximal left anterior descending artery, permitting
measurement of coronary blood flow velocities. A dosage of
5,000 IU of heparin was given intravenously. Blood flow
velocity was recorded continuously during administration of
the study agents. First, adenosine (80 and 160 mg/min over
5 min each; Adrekar, Sanofi-Winthrop, Munich, Germany)
was infused into the left coronary system to achieve maximal
(endothelium-independent) coronary flow. Second, intra-
coronary acetylcholine ([ACh] 1 and 30 mg/min over 5 min
each; Acetylcholine Dispersa, Germering, Germany) was
infused to investigate epicardial and microvascular endothe-
lial vasomotor function (estimated final blood concentra-
tions in the coronary bed of 1027 and 3 3 1028 mol/l).
Third, intracoronary nifedipine (Adalat; Bayer AG,
Leverkusen, Germany) was administered as a bolus
Abbreviations and Acronyms
ACh 5 acetylcholine
CRP 5 C-reactive protein
CFVR 5 coronary flow velocity reserve
HMG-CoA 5 3-hydroxy-3-methylglutaryl coenzyme A
IL 5 interleukin
IVUS 5 intravascular ultrasound
TNF 5 tumor necrosis factor
Table 1. Patient Characteristics
Group 1
(Hypercholesterolemia
Adequately Treated,
n 5 21)
Group 2
(Hypercholesterolemia
Inadequately Controlled,
n 5 19)
Group 3
(Without
Hypercholesterolemia,
n 5 40)
Time after transplantation (months) 23 6 9 26 6 8 24 6 11
Recipient age (yr) 52 6 7 50 6 8 49 6 10
Donor age (yr) 38 6 7 41 6 8 36 6 9
Ischemic time (min) 188 6 37 173 6 27 177 6 21
Frequency of CMV mismatches 57% 53% 50%
Number of HLA mismatches 4.3 6 1.0 4.5 6 0.8 4.3 6 0.8
Number of treated rejection episodes 0.4 6 0.6 0.7 6 0.5 0.7 6 0.4
Frequency of corticosteroids 62% 74% 68%
Frequency of ACE-inhibitor treatment 33% 26% 25%
Serum lipids
Total cholesterol (mg/dl) 192 6 22 231 6 20* 179 6 31
Triglycerides (mg/dl) 177 6 34 210 6 29* 155 6 26
*p , 0.01 vs. groups 1 and 3.
ACE 5 angiotensin-converting enzyme; CMV 5 cytomegalovirus; HLA 5 human leukocyte antigen.
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(0.2 mg/30 s) to achieve maximal (endothelium-
independent) epicardial vasodilation. At the end of each
infusion, coronary arteriography was performed and ana-
lyzed off-line using quantitative coronary angiography.
Coronary flow reserve. The coronary flow velocity reserve
(CFVR) as a marker of the microvascular integrity was deter-
mined by the ratio of the maximal coronary flow velocity
(cm/s) after pharmacological stimulation to the basal flow
velocity. The coronary flow is critically controlled at the level of
the resistance vessels, provided no severe stenosis is present in
the epicardial arteries. In this study, no epicardial constriction
.50% in response to ACh was observed. Therefore, diameter
changes were not included in the calculation of CFVR.
Coronary microvascular endothelial dysfunction has been de-
fined as CFVR ,2 in response to ACh (10).
Quantitative coronary angiography. Quantitative coro-
nary angiography was performed to investigate epicardial
vasomotor response using a computerized automatic-
analysis system (HICOR, Siemens, Erlangen, Germany).
Nonstenotic proximal and distal coronary arterial segments
identified between easily visualized branch points were
selected for analysis in the left anterior descending artery.
Responses of the coronary segments to the different stimuli
were expressed as percent change versus control value. The
diameter change for each vessel was calculated on the basis
of the average of the two segments. Intraobserver and
interobserver variability showed high reproducibility (r .
0.89, p , 0.001). Epicardial endothelial dysfunction has
been defined as .10% diameter reduction in response to
ACh compared with baseline (10).
IVUS. Immediately after Doppler flow measurement,
IVUS was performed to detect atherosclerotic plaques not
visible with angiography. The imaging system consisted of a
30-MHz ultrasound transducer enclosed within an acoustic
housing on the tip of a 2.9F flexible, rapid-exchange
catheter (CVIS Inc., Sunnyvale, California). The catheter
was advanced to the distal left anterior descending or
circumflex artery, carefully observing a lumen-IVUS
catheter-diameter ratio of .1.5. During the subsequent
standardized pullback maneuver, images were documented
on SVHS videotape for further off-line analysis. The three
sites with the most severe intimal proliferation were evalu-
ated, and the averaged maximal intimal thickness was
calculated (11). Maximal intimal thickness was measured as
the greatest distance from the intimal leading edge to
media-adventitia border. Measurements of lumen and vessel
area were made of the three most severely stenosed sites and
averaged. These analyses were performed by observers
without knowledge of the results of the endothelial function
or the lipid and cytokine levels.
Cytokine measurements. Measurement of cytokines using
enzyme-linked immunosorbent assay was performed as
described in detail elsewhere (9).
Statistical analysis. Continuous variables are presented as
mean 6 SD. When comparing three groups, one-way
analysis of variance was followed by the Student-Newman-
Keuls post hoc test for statistical significance. For compar-
isons within the same individuals over time (prospective
study groups), the paired samples t test was used. Discrete
variables are presented as percentages. The Pearson chi-
square test was used to determine significant differences.
Statistical significance was assumed if the null hypothesis
could be rejected at the 0.05 probability level.
RESULTS
Coronary intimal thickening. Averaged maximal intimal
thickness in groups 1 and 2 were similar and significantly
(p , 0.01 and p , 0.05, respectively) larger than intimal
thickness in group 3: 0.7 6 0.3 mm (group 1), 0.6 6
0.4 mm (group 2) and 0.4 6 0.2 mm (group 3). Impor-
tantly, lumen areas in groups 1 and 3 were similar and
significantly (p , 0.05) larger than lumen areas in group 2:
7.5 6 0.6 mm2 (group 1), 6.3 6 0.5 mm2 (group 2) and
7.9 6 0.3 mm2 (group 3).
Coronary vasomotor response. Results are referred to the
highest dosage administered of each drug. The values of
heart rate and mean blood pressure after drug administra-
tion were not significantly altered compared to baseline
(data not shown). Epicardial luminal diameter constriction
in response to ACh was significantly more pronounced in
group 2 compared with group 1 and group 3 patients (p ,
0.05; Fig. 1). Vasoconstrictor response to ACh in group 3
tended to be increased compared with group 1 (p 5 0.07).
Endothelium-independent responses to adenosine and ni-
fedipine were similar in all groups (data not shown).
Moreover, endothelium-dependent flow velocity increase
was similar in group 1 and group 3; the increases were
significantly greater than those in group 2 (p , 0.05; Fig. 2).
Endothelium-independent microvascular responses were
comparable between the groups (data not shown).
Cytokine concentrations. Plasma cytokine concentrations
in the coronary sinus and aortic root are depicted in Table
2. Cardiac IL-6 and TNF-a release was significantly
lower in group 1 than it was in groups 2 and 3 (for re-
spective values in group 1, 2 and 3: IL-6: 22 6 2 pg/ml,
3 6 4 pg/ml and 6 6 6 pg/ml; all p , 0.05; TNF-a: 21 6
4 ng/ml, 7 6 5 ng/ml and 6 6 4 ng/ml; all p , 0.01).
Interleukin-2R concentrations were similar in all groups.
Figure 1. Epicardial endothelium-dependent vasomotor response. Epicar-
dial diameter change in response to intracoronary acetylcholine (ACh).
Group 1 5 patients with hypercholesterolemia adequately controlled;
group 2 5 patients with hypercholesterolemia inadequately controlled;
group 3 5 patients without hypercholesterolemia. *p , 0.01 vs. group 2;
**p , 0.05 vs. group 2.
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Prospective study. Characteristics of plaque and coronary
hemodynamics, as well as lipid and cytokine concentrations
before and after simvastatin treatment are shown in Table 3.
Coronary epicardial and microvascular endothelial dysfunc-
tion significantly improved after one year of simvastatin
treatment and was associated with a decrease in cardiac IL-6
and TNF-a release and an increase in coronary lumen area
(Table 3). In contrast, functional and morphological coro-
nary features as well as cytokine concentrations were un-
changed in heart transplant recipients without simvastatin
treatment.
DISCUSSION
This study demonstrates that simvastatin treatment in
transplant patients is associated with a better epicardial and
microvascular endothelial function dependent on the
amount of cholesterol lowering. These changes were asso-
ciated with decreased cardiac cytokine release demonstrat-
ing simvastatin-mediated anti-inflammatory activity.
Statins and inflammation. Our findings support the no-
tion of HMG-CoA reductase inhibitors as immuno-
modulating agents with downregulation of inflammatory
responses (12). Atherogenic lipoproteins, in particular low-
density lipoprotein, are potent proinflammatory stimuli
eliciting a broad spectrum of cellular responses. Effectively
lowering the concentrations of these lipoproteins may,
therefore, normalize systemic inflammation markers. How-
ever, the cytokine concentrations in the adequately treated
group was, in fact, lower than the concentrations in normo-
cholesterolemic subjects, pointing to an at least partial
lipid-independent mechanism. Importantly, in the Choles-
terol And Recurrent Events trial, mean CRP levels de-
creased nearly 40% during a five-year period among those
patients allocated to pravastatin versus placebo, an effect not
related to pravastatin-induced changes in low-density li-
poprotein cholesterol (13).
Statins, endothelial function and vascular remodeling.
Moreover, our results are consistent with previous studies in
nontransplant humans that demonstrated improvement in
peripheral and coronary endothelial function after treatment
with inhibitors of the HMG-CoA reductase (3–5). Intimal
thickening as an early marker of morphological allograft
vasculopathy was significantly elevated in patients with
hypercholesterolemia not adequately controlled. This is
consistent with two prospective clinical trials demonstrating
significantly reduced increases of the intimal thickness after
cardiac transplantation in patients treated with HMG-CoA
reductase inhibitors (1,2). They also reported on a reduced
prevalence of acute rejection episodes and better survival. In
contrast, in this study intimal thickness was increased in
patients with hypercholesterolemia adequately controlled
compared with patients without a history of hypercholes-
terolemia. This may result from a relatively short treatment
period (8 6 5 months) not sufficient enough to have impact
on atherosclerotic plaque regression. However, coronary
lumen area in adequately controlled hypercholesterolemic
patients was significantly increased compared with uncon-
trolled patients demonstrating adaptive coronary remodel-
ing. Interestingly, endothelial function may modulate the
process of vascular remodeling (14). In fact, in the present
prospective study, simvastatin treatment reduced coronary
artery constriction and increased coronary blood flow re-
sponses during intracoronary acetylcholine infusion, reflect-
ing improved endothelial-dependent action in conduit cor-
onary arteries and coronary microvessels, respectively.
Additionally, simvastatin treatment was associated with an
improvement in coronary lumen area that resulted not from
Table 2. Cytokines
Group 1
(Hypercholesterolemia
Adequately Treated,
n 5 21)
Group 2
(Hypercholesterolemia
Inadequately Controlled,
n 5 19)
Group 3
(Without
Hypercholesterolemia,
n 5 40)
IL-6 (coronary sinus), pg/ml 12 6 10 18 6 7 15 6 12
IL-6 (aorta), pg/ml 15 6 6 16 6 10 11 6 9
IL-6 (transcardiac gradient), pg/ml 22 6 2† 3 6 4 6 6 3
TNF-a (coronary sinus), ng/ml 17 6 9 21 6 9 22 6 7
TNF-a (aorta), ng/ml 17 6 10 15 6 12 17 6 7
TNF-a (transcardiac gradient), ng/ml 21 6 4* 7 6 5 6 6 4
IL-2R (coronary sinus), ng/ml 0.8 6 0.6 0.7 6 0.5 0.7 6 0.4
IL-2R (aorta), ng/ml 0.9 6 0.4 0.7 6 0.7 0.6 6 0.9
IL-2R (transcardiac gradient), ng/ml 20.03 6 0.05 0.03 6 0.1 0.06 6 0.1
*p , 0.01 vs. groups 2 and 3; †p , 0.05 vs. groups 2 and 3.
IL 5 interleukin; TNF 5 tumor necrosis factor; transcardiac gradient 5 coronary sinus minus aortic concentrations.
Figure 2. Microvascular endothelium-dependent vasomotor response.
Coronary flow velocity increase in response to intracoronary acetylcholine
(ACh). Group 1 5 patients with hypercholesterolemia adequately con-
trolled; group 2 5 patients with hypercholesterolemia inadequately con-
trolled; group 3 5 patients without hypercholesterolemia. *p , 0.05 vs.
groups 1 and 3.
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a decrease in intimal area but from an increase in vessel area,
reflecting vascular remodeling.
Study limitations. The limitations of intracoronary ultra-
sound imaging and Doppler flow velocity measurement
have been described in detail elsewhere (15,16). Focusing of
the three worst sites of each vessel may underestimate the
severity of diffuse intimal thickening. Therefore, further
studies with plaque volumetry in several predefined seg-
ments may improve the comparability of the measurements.
Moreover, we cannot rule out that functional and morpho-
logical coronary features were different between the three
groups before statin treatment. Indeed, this study is mainly
a cross-sectional study, and findings may warrant confirma-
tion through a larger prospective study.
In summary, the better epicardial and microvascular
endothelial vasomotor function in heart transplant recipi-
ents treated with simvastatin may result, at least in part,
from an attenuated inflammatory response in the cardiac
allograft. Improvement in endothelial dysfunction was as-
sociated with adaptive coronary remodeling.
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Table 3. Changes in Lipid and Cytokine Values, Intimal Thickening and Coronary Hemodynamics (Prospective Study)
Simvastatin Group (n 5 11) Control Group (n 5 9)
Baseline
After 12 Months
Treatment With
Simvastatin Baseline After 12 Months
Months after transplantation 15 6 7 25 6 4 12 6 4 26 6 3
Total cholesterol (mg/dl) 233 6 31 176 6 22† 184 6 27 195 6 33
Triglycerides (mg/dl) 217 6 29 182 6 34* 167 6 29 180 6 31
% diameter change to ACh 210 6 5 23 6 5* 28 6 5 26 6 9
% flow velocity increase to ACh 132 6 34 176 6 29† 142 6 26 154 6 35
Coronary lumen area 6.5 6 0.6 7.3 6 0.5* 7.0 6 0.7 7.2 6 0.4
Averaged maximal intimal thickness (mm) 0.58 6 0.11 0.60 6 0.08 0.52 6 0.09 0.55 6 0.12
Transcardiac IL-2R gradient 0.6 6 0.9 0.4 6 0.5 1.2 6 0.4 0.6 6 0.9
Transcardiac IL-6 gradient 3.9 6 0.5 20.2 6 0.7* 2.6 6 1.0 1.9 6 0.8
Transcardiac TNF-a gradient 6.0 6 4 21.4 6 6† 3.7 6 2.0 3.8 6 4.9
*p , 0.05 vs. baseline; †p , 0.01 vs. baseline.
ACh 5 acetylcholine; IL 5 interleukin; TNF 5 tumor necrosis factor; transcardiac gradient 5 coronary sinus minus aortic concentrations.
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